Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
53 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Simcere Pharmaceutical Group - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Simcere Pharmaceutical Group - Product Pipeline Review - 2016', provides an overview of the Simcere Pharmaceutical Group's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Simcere Pharmaceutical Group, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Simcere Pharmaceutical Group - The report provides overview of Simcere Pharmaceutical Group including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Simcere Pharmaceutical Group's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Simcere Pharmaceutical Group's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons to Buy - Evaluate Simcere Pharmaceutical Group's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Simcere Pharmaceutical Group - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Simcere Pharmaceutical Group's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Simcere Pharmaceutical Group Snapshot 6 Simcere Pharmaceutical Group Overview 6 Key Information 6 Key Facts 6 Simcere Pharmaceutical Group - Research and Development Overview 7 Key Therapeutic Areas 7 Simcere Pharmaceutical Group - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Combination Treatment Modalities 12 Pipeline Products - Partnered Products 13 Partnered Products/Combination Treatment Modalities 14 Simcere Pharmaceutical Group - Pipeline Products Glance 15 Simcere Pharmaceutical Group - Late Stage Pipeline Products 15 Phase III Products/Combination Treatment Modalities 15 Simcere Pharmaceutical Group - Clinical Stage Pipeline Products 16 Phase II Products/Combination Treatment Modalities 16 Phase I Products/Combination Treatment Modalities 17 Simcere Pharmaceutical Group - Early Stage Pipeline Products 18 IND/CTA Filed Products/Combination Treatment Modalities 18 Preclinical Products/Combination Treatment Modalities 19 Discovery Products/Combination Treatment Modalities 20 Simcere Pharmaceutical Group - Drug Profiles 21 SIM-071201 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 bendamustine hydrochloride 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 (amlodipine besylate + irbesartan) 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 APX-003 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 metatinib tromethamine 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 abatacept 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 BMS-817378 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 OSI-930 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 SIM-010603 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 SIM-0710 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 BMS-795311 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 SCR-1693 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 SIM-89 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Small Molecule to Inhibit Bruton's Tyrosine Kinase for Arthritis 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Small Molecule for Cancer 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Simcere Pharmaceutical Group - Pipeline Analysis 38 Simcere Pharmaceutical Group - Pipeline Products by Target 38 Simcere Pharmaceutical Group - Pipeline Products by Route of Administration 40 Simcere Pharmaceutical Group - Pipeline Products by Molecule Type 41 Simcere Pharmaceutical Group - Pipeline Products by Mechanism of Action 42 Simcere Pharmaceutical Group - Recent Pipeline Updates 44 Simcere Pharmaceutical Group - Dormant Projects 49 Simcere Pharmaceutical Group - Locations And Subsidiaries 50 Head Office 50 Other Locations & Subsidiaries 50 Appendix 52 Methodology 52 Coverage 52 Secondary Research 52 Primary Research 52 Expert Panel Validation 52 Contact Us 52 Disclaimer 53
List of Tables Simcere Pharmaceutical Group, Key Information 6 Simcere Pharmaceutical Group, Key Facts 6 Simcere Pharmaceutical Group - Pipeline by Indication, 2016 8 Simcere Pharmaceutical Group - Pipeline by Stage of Development, 2016 10 Simcere Pharmaceutical Group - Monotherapy Products in Pipeline, 2016 11 Simcere Pharmaceutical Group - Combination Treatment Modalities in Pipeline, 2016 12 Simcere Pharmaceutical Group - Partnered Products in Pipeline, 2016 13 Simcere Pharmaceutical Group - Partnered Products/ Combination Treatment Modalities, 2016 14 Simcere Pharmaceutical Group - Phase III, 2016 15 Simcere Pharmaceutical Group - Phase II, 2016 16 Simcere Pharmaceutical Group - Phase I, 2016 17 Simcere Pharmaceutical Group - IND/CTA Filed, 2016 18 Simcere Pharmaceutical Group - Preclinical, 2016 19 Simcere Pharmaceutical Group - Discovery, 2016 20 Simcere Pharmaceutical Group - Pipeline by Target, 2016 38 Simcere Pharmaceutical Group - Pipeline by Route of Administration, 2016 40 Simcere Pharmaceutical Group - Pipeline by Molecule Type, 2016 41 Simcere Pharmaceutical Group - Pipeline Products by Mechanism of Action, 2016 43 Simcere Pharmaceutical Group - Recent Pipeline Updates, 2016 44 Simcere Pharmaceutical Group - Dormant Developmental Projects,2016 49 Simcere Pharmaceutical Group, Subsidiaries 50
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.